Item 1.01 Entry into a Material Definitive Agreement.

As previously disclosed, on February 16, 2024, Biotronik SE & Co. KG ("Biotronik") and VascoMed GmbH ("VascoMed", and together with Biotronik, the "BIO Parties") commenced arbitration ("Arbitration") against Acutus Medical, Inc. (the "Company") with the American Arbitration Association, alleging that the Company breached its contractual obligations under five agreements relating to the licensing, manufacturing and distribution of medical devices: (i) the License and Distribution Agreement with the BIO Parties entered into on July 2, 2019 (the "LDA"); (ii) the Global Alliance for Biotronik Product Distribution Agreement with Biotronik entered into on May 11, 2020 and the Global Alliance for Acutus Product Distribution Agreement, as amended, with Biotronik entered into on May 25, 2020 (collectively, the "Distribution Agreements"); (iii) the Feasibility and Development Agreement with Biotronik entered into on June 3, 2021 (the "F&D Agreement"); and (iv) the Manufacturing and Supply Agreement with Biotronik entered into on April 19, 2022 (the "MSA", and together with the LDA, the Distribution Agreements and the F&D Agreement, the "Relevant Agreements"). Further descriptions of the LDA, the Distribution Agreements and the F&D Agreement are included in the Company's Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the "SEC") on June 7, 2021 and the Company's Registration Statement on Form S-1 filed with the SEC on July 15, 2020, as applicable, which descriptions are incorporated by reference herein. The foregoing descriptions of the LDA, the Distribution Agreements and the F&D Agreement are not complete and are qualified in their entirety by the respective agreements, copies of which are filed as Exhibits 10.4, 10.5, 10.6 and 10.33, respectively, to the Company's Annual Report on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 24, 2023.

On October 15, 2024, the Company and the BIO Parties entered into a Settlement Agreement and Release (the "Settlement Agreement") terminating the Relevant Agreements (except for certain surviving obligations specified therein), settling the Arbitration relating to the Relevant Agreements and releasing and discharging each party of all claims against the other, including any claims that were or could have been asserted in the Arbitration. Capitalized terms used but not otherwise defined herein shall have the meanings given to them in the Settlement Agreement.

Pursuant to the Settlement Agreement, the Company must pay to Biotronik (i) an initial settlement payment of approximately $2.6 million; (ii) contingent payments of (x) in the event of a Qualifying Asset Sale, an amount equal to 50% of the aggregate cash consideration received; (y) in the event of a Change of Control of the Company involving a Competitive Company, (A) initial amounts of $8 million and 5% of the aggregate upfront consideration received, with the latter not to exceed approximately $25 million ("Agreed Upfront Consideration") and (B) additional amounts if additional consideration is received, up to approximately $25 million in aggregate (including the Agreed Upfront Consideration); and (z) in the event of a Change of Control not involving a Competitive Company, with certain exceptions, an amount equal to 25% of the aggregate cash consideration received.

The foregoing description of the Settlement Agreement does not purport to be complete and is qualified in its entirety by reference to the Settlement Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated by reference herein.